Search

Ajay Kumar Goel

from Dallas, TX
Age ~56
Get Report
Also known as:
Ajay K Goel, Lalima Goel, Lauma Goel, Ajay Kumar
Related to:
Lokesh Sundararaj, 41
Connected to:
Aman Goel, 35Amar K Goel, 48Anjali Goel, 47Ansha Goel, 35Aseem Goel, 31Asha G Goel, 73Ashok K Goel, 71Atul Goel, 56Avnish K Goel, 54Bhawna Goel, 82

Ajay Goel Phones & Addresses

  • Dallas, TX
  • Issaquah, WA
  • Highlands Ranch, CO
  • 5020 Lake Shore Dr, Chicago, IL 60615
  • Pleasanton, CA
  • Houston, TX
  • Chesterfield, MO
  • Irving, TX
  • Los Gatos, CA
  • Fremont, CA
  • Cadiz, CA
  • Saint Louis, MO
  • Macungie, PA

Specialities

Buyer's Agent • Listing Agent

Professional Records

Medicine Doctors

Ajay Goel Photo 1

Ajay Goel

View page
Specialties:
Gastroenterology
Work:
Ajay Goel MD
1617 N James St STE 400, Rome, NY 13440
(315) 337-0539 (phone), (315) 337-0645 (fax)
Education:
Medical School
Maulana Azad Med Coll, Delhi Univ, New Delhi, Delhi, India
Graduated: 1979
Procedures:
Colonoscopy
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Hemorrhoid Procedures
Sigmoidoscopy
Upper Gastrointestinal Endoscopy
Esophageal Dilatation
Conditions:
Gastroesophageal Reflux Disease (GERD)
Abdominal Hernia
Acne
Acute Myocardial Infarction (AMI)
Acute Pancreatitis
Languages:
English
Description:
Dr. Goel graduated from the Maulana Azad Med Coll, Delhi Univ, New Delhi, Delhi, India in 1979. He works in Rome, NY and specializes in Gastroenterology. Dr. Goel is affiliated with Rome Memorial Hospital.
Ajay Goel Photo 2

Ajay S Goel

View page
Specialties:
Internal Medicine
Gastroenterology
Education:
Maulana Azad Medical College (1979)

Resumes

Resumes

Ajay Goel Photo 3

Professor And Founding Chair, Department Of Molecular Diagnostics And Experimental Therapeutics

View page
Location:
Duarte, CA
Industry:
Research
Work:
Beckman Research Institute of City of Hope Comprehensive Cancer Center
Professor and Founding Chair, Department of Molecular Diagnostics and Experimental Therapeutics
City of Hope
Professor and Founding Chair, Department of Molecular Diagnostics and Experimental Therapeutics
Baylor University
Adjunct Professor
Baylor Scott & White Health
Director, Center For Gastrointestinal Research; Center For Epigenetics,Cancer Prevention and Genomics
Baylor Scott & White Health
Investigator and Professor
Education:
Panjab University,Chandigarh 1991 - 1996
Doctorates, Doctor of Philosophy, Biophysics, Philosophy Panjab University,Chandigarh 1988 - 1990
Master of Science, Masters, Biophysics Panjab University,Chandigarh 1985 - 1988
Bachelors, Bachelor of Science, Biophysics
Skills:
Molecular Biology
Cancer
Clinical Research
Genomics
Biochemistry
Biomarkers
Epigenetics
Oncology
Gastrointestinal Oncology
Colorectal Cancer
Diagnostic Biomarkers
Cancer Research
Dna Methylation
Noncoding Rnas
Micrornas
Predicitve Biomarkers
Chemoprevention
Dietary Polyphenols
Chemotherapy
Stem Cells
Gastric Cancer
Pancreatic Cancer
Rectal Cancer
Liquid Biopsy
Personalized Medicine
Early Detection
Prognostic Biomarker
Colon Cancer
Life Sciences
Cell Culture
Languages:
English
Hindi
Punjabi
Ajay Goel Photo 4

Ajay Goel

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ajay Goel
President
AAAS CONSULTING SERVICES INCORPORATED
6216 Velasco Ave, Dallas, TX 75214
6149 Marquita Ave, Dallas, TX 75214
Ajay Goel
SILICOMM CORPORATION
Ajay Goel
DREAMJEWELRY.COM, INC

Publications

Amazon

Mathematics & Statistics

View page
Author

Alka Goel Ajay Goel

Binding

Paperback

Publisher

Taxmann Allied Services Pvt. Ltd.

ISBN #

8174968229

EAN Code

9788174968227

ISBN #

1

Us Patents

Micrornas (Mirna) As Biomarkers For The Identification Of Familial And Non-Familial Colorectal Cancer

View page
US Patent:
20120088687, Apr 12, 2012
Filed:
Oct 7, 2011
Appl. No.:
13/269059
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Francesc Balaguer - Barcelona, ES
Meritxell Gironella i Cos - Barcelona, ES
Antoni Castells i Garangou - Barcelona, ES
Leticia Moreira Ruiz - Barcelona, ES
Juan Jose Lozano Salvatella - Barcelona, ES
Assignee:
Baylor Research Institute - Dallas TX
Centro de Investigacion en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD) - Barcelona
Hospital Clinic de Barcelona - Barcelona
International Classification:
C40B 30/04
C40B 40/06
US Classification:
506 9, 506 16
Abstract:
A technique for the analysis of global miRNA signatures including a larger panel of miRNAs in various groups of well-characterized colorectal cancers (CRCs) is described in the instant invention. The results presented herein provide a large list of miRNAs that are dysregulated in CRC compared to the normal colonic tissue, and, more importantly, the present invention shows for the first time that Lynch syndrome and sporadic MSI tumors exhibit a different miRNA signature that distinguishes them.

Msh3 Expression Status Determines The Responsiveness Of Cancer Cells To The Chemotherapeutic Treatment With Parp Inhibitors And Platinum Drugs

View page
US Patent:
20120207856, Aug 16, 2012
Filed:
Feb 10, 2012
Appl. No.:
13/370752
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Minoru Koi - Dallas TX, US
Masanobu Takahashi - Richardson TX, US
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
A61K 33/24
A61K 31/255
A61K 31/196
A61K 31/675
A61K 31/655
C07K 14/47
A61K 31/4745
C12Q 1/68
G01N 33/53
G01N 33/566
G01N 33/577
A61P 35/00
A61K 31/175
A61K 31/704
US Classification:
424649, 514589, 514517, 514567, 514110, 514151, 514 34, 514283, 435 612, 436501, 435 723, 530350
Abstract:
Methods for treating a patient at risk for or diagnosed with colorectal cancer are disclosed herein. The method of the present invention determines the overall expression of MSH3 in cells suspected of being colorectal cancer cells from the patient and predicting the efficacy of therapy with a genotoxic anti-neoplastic agent for treating the patient, wherein a decrease in the overall expression of MSH3 in the patient cells when compared to the expression of MSH3 in normal colorectal cells indicates a predisposition to responsiveness to genotoxic anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the genotoxic anti-neoplastic agent therapy to patients.

Long Interspersed Nuclear Elements (Line-1) And Alu Hypomethylation As Biomarkers For Colorectal Cancer Metastasis

View page
US Patent:
20120237929, Sep 20, 2012
Filed:
Feb 29, 2012
Appl. No.:
13/408947
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Keun Hur - Dallas TX, US
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX
International Classification:
C12Q 1/68
C07H 21/04
US Classification:
435 611, 536 235
Abstract:
A method for determining a colorectal cancer metastasis in a human subject suffering from a primary colorectal cancer (CRC) is described herein. The method of the present invention comprises the steps of: i) identifying the human subject suffering from the primary CRC, ii) obtaining one or more biological samples from the human subject, iii) detecting a methylation level of Alu, LINE-1, or both in the one or more biological samples, and iv) increasing the level of the colorectal metastatic stage in the human subject when the methylation level of Alu, LINE-1 is lower compared to a corresponding control methylation level of Alu, LINE-1.

Line-1 Hypomethylation As A Biomarker For Early-Onset Colorectal Cancer

View page
US Patent:
20120238463, Sep 20, 2012
Filed:
Mar 14, 2012
Appl. No.:
13/419744
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Francesc Balaguer - Barcelona, ES
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
C12Q 1/68
C40B 30/04
C40B 30/00
US Classification:
506 9, 435 611, 506 7
Abstract:
A method for detecting an early-onset of colorectal cancer in a human subject is disclosed herein. The method comprises the steps of: (i) identifying the human subject suspected of suffering from a colorectal cancer, (ii) obtaining one or more biological samples from the human subject; (iii) determining a LINE-1 methylation level for the one or more biological samples; and (iv) comparing the LINE-1 methylation level to a LINE-1 methylation control level, wherein a higher degree of the LINE-1 methylation level is indicative of an early-onset colorectal cancer.

Changes In The Expression Of Mir-200C/141 Cluster Of Micrornas As Biomarkers For Epithelial-To-Mesenchymal Transition In Human Colorectal Cancer Metastasis

View page
US Patent:
20120264131, Oct 18, 2012
Filed:
Feb 29, 2012
Appl. No.:
13/408836
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Keun Hur - Dallas TX, US
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX
International Classification:
C12Q 1/68
C07H 21/02
US Classification:
435 612, 435 614, 536 231
Abstract:
The present invention includes methods, kits and biomarkers for detecting and determining the development of colorectal cancer (CRC) metastasis based on changes in the expression pattern of one or more microRNAs (miR) or miR clusters that include the miR-200/141 family.

Detecting Dna Mismatch Repair-Deficient Colorectal Cancers

View page
US Patent:
20120295267, Nov 22, 2012
Filed:
May 7, 2012
Appl. No.:
13/465668
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Takeshi Nagasaka - Okayama, JP
Assignee:
Baylor Research Institute - Dallas TX
International Classification:
C12Q 1/68
C12M 1/40
US Classification:
435 612, 4352872
Abstract:
Use of a CAT25 mononucleotide marker in a novel tetraplex PCR for the detection of MSH6-defective colorectal cancers (CRCs) is described herein. The tetraplex PCR of the present invention offers a facile, robust, less expensive (compared to the original pentaplex assay), highly sensitive, and specific assay for the identification of microsatellite instability (MSI) in CRCs.

Novel Dna Hypermethylation Diagnostic Biomarkers For Colorectal Cancer

View page
US Patent:
20130288247, Oct 31, 2013
Filed:
Oct 4, 2011
Appl. No.:
13/876568
Inventors:
Yuriko Mori - Baltimore MD, US
Stephen Meltzer - Lutherville MD, US
Ajay Goel - Dallas TX, US
Clement Boland - Dallas TX, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The present invention relates to the field of cancer. More specifically, the present invention relates to the use of biomarkers to detect colorectal cancer. In one aspect, the present invention provides methods for qualifying colorectal cancer status including, but not limited to, diagnosis, prognosis, and risk stratification, in patients. In one embodiment, a method for diagnosing colorectal cancer (CRC) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) comparing the methylation levels of the one or more biomarkers with predefined methylation levels of the same biomarkers that correlate to a patient having CRC and predefined methylation levels of the same biomarkers that correlate to a patient not having CRC, wherein a correlation to one of the predefined methylation levels provides the diagnosis.

Identification Of Micrornas (Mirnas) In Fecal Samples As Biomarkers For Gastroenterological Cancers

View page
US Patent:
20110086353, Apr 14, 2011
Filed:
Oct 8, 2010
Appl. No.:
12/901467
Inventors:
Ajay Goel - Dallas TX, US
C. Richard Boland - Dallas TX, US
Alexander Link - Dallas TX, US
Francesc Balaguer - Dallas TX, US
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX
International Classification:
C12Q 1/68
C12P 19/34
US Classification:
435 6, 435 912, 435 9121
Abstract:
A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases.
Control profile
Ajay Kumar Goel from Dallas, TX, age ~56 Get Report